Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
| Market Cap (Intraday) | 23.81B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $190.85 |
| 50-Day MA | $198.79 |
| 200-Day MA | $208.34 |
Alnylam Pharmaceuticals Inc Stock, NASDAQ:ALNY
675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142
Phone: +1.617.551.8200
Number of Employees: 2002
Description
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.